BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 32,250,000 shares, a growth of 5.6% from the March 15th total of 30,550,000 shares. Based on an average daily trading volume, of 3,290,000 shares, the days-to-cover ratio is presently 9.8 days.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX opened at $4.58 on Thursday. The company’s fifty day moving average is $5.25 and its 200 day moving average is $5.63. BioCryst Pharmaceuticals has a fifty-two week low of $4.45 and a fifty-two week high of $9.06. The stock has a market capitalization of $944.17 million, a PE ratio of -3.88 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million for the quarter, compared to the consensus estimate of $89.19 million. As a group, research analysts forecast that BioCryst Pharmaceuticals will post -0.68 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.29.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company’s stock valued at $106,405,000 after acquiring an additional 2,371,401 shares during the last quarter. BlackRock Inc. increased its position in BioCryst Pharmaceuticals by 4.5% during the second quarter. BlackRock Inc. now owns 15,495,703 shares of the biotechnology company’s stock valued at $109,090,000 after acquiring an additional 670,905 shares during the last quarter. Avoro Capital Advisors LLC increased its position in BioCryst Pharmaceuticals by 13.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company’s stock valued at $78,170,000 after acquiring an additional 1,500,000 shares during the last quarter. State Street Corp increased its position in BioCryst Pharmaceuticals by 7.7% during the second quarter. State Street Corp now owns 12,263,969 shares of the biotechnology company’s stock valued at $86,338,000 after acquiring an additional 874,346 shares during the last quarter. Finally, Braidwell LP increased its position in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company’s stock valued at $34,254,000 after acquiring an additional 355,497 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.